Y
Yasuo Terauchi
Researcher at Yokohama City University
Publications - 413
Citations - 31656
Yasuo Terauchi is an academic researcher from Yokohama City University. The author has contributed to research in topics: Diabetes mellitus & Type 2 diabetes. The author has an hindex of 67, co-authored 382 publications receiving 29461 citations. Previous affiliations of Yasuo Terauchi include Texas A&M University & University of Tokyo.
Papers
More filters
Journal ArticleDOI
Pravastatin Potentiates Increases in Serum Adiponectin Concentration in Dyslipidemic Patients Receiving Thiazolidinedione: the DOLPHIN Study
Uru Nezu,Uru Nezu,Seishi Tsunoda,Hideki Yoshimura,Tetsuo Kuwabara,Shoken Tomura,Yukio Seki,Mizuki Kaneshiro,Hiroshi Kamiyama,Yukina Harada,Erina Shigematsu,Kazutaka Aoki,Tadashi Yamakawa,Kenji Ohshige,Yutaka Natsumeda,Yasuo Terauchi +15 more
TL;DR: Pravastatin increased the serum adiponectin concentration in Japanese dyslipidemic patients without previous coronary artery disease and this effect was seen synergistically in combination with thiazolidinedione.
Journal ArticleDOI
Is a Switch From Insulin Therapy to Liraglutide Possible in Japanese Type 2 Diabetes Mellitus Patients
Takehiro Kawata,Akira Kanamori,Akira Kubota,Hajime Maeda,Hikaru Amamiya,Masahiko Takai,Hideaki Kaneshige,Fuyuki Minagawa,Kotaro Iemitsu,Mizuki Kaneshiro,Masashi Ishikawa,Hiroshi Takeda,Tetsurou Takuma,Atsuko Mokubo,Hideo Machimura,Mitsuo Obana,Masaaki Miyakawa,Yoshikazu Naka,Daisuke Suzuki,Yasuo Terauchi,Masao Toyoda,Yasushi Tanaka,Ikuro Matsuba +22 more
TL;DR: Switching from insulin to liraglutide therapy is possible for carefully selected patients and daily insulin dosage and duration of insulin therapy appear to be clinically useful indicators for the efficacy of lirAGlutid therapy.
Journal ArticleDOI
Safety, tolerability and efficacy of lixisenatide as monotherapy in Japanese patients with type 2 diabetes mellitus: An open-label, multicenter study.
TL;DR: To assess the overall safety of lixisenatide monotherapy in Japanese patients with type 2 diabetes mellitus, a randomised, double-blind, placebo-controlled trial is conducted.
Journal ArticleDOI
Effects of liraglutide and empagliflozin added to insulin therapy in patients with type 2 diabetes: A randomized controlled study
TL;DR: Liraglutide and empagliflozin suppress cardiovascular events and their long‐term combined use with insulin therapy or direct comparisons of these drugs are limited.
Journal ArticleDOI
Factors Predicting Therapeutic Efficacy of Combination Treatment With Sitagliptin and Insulin in Type 2 Diabetic Patients: The ASSIST-K Study
Masashi Ishikawa,Masahiko Takai,Hajime Maeda,Akira Kanamori,Akira Kubota,Hikaru Amemiya,Takashi Iizuka,Kotaro Iemitsu,Tomoyuki Iwasaki,Goro Uehara,Shinichi Umezawa,Mitsuo Obana,Hideaki Kaneshige,Mizuki Kaneshiro,Takehiro Kawata,Nobuo Sasai,Tatsuya Saito,Tetsuo Takuma,Hiroshi Takeda,Keiji Tanaka,Nobuaki Tsurui,Shigeru Nakajima,Kazuhiko Hoshino,Shin Honda,Hideo Machimura,Kiyokazu Matoba,Fuyuki Minagawa,Nobuaki Minami,Yukiko Miyairi,Atsuko Mokubo,Tetsuya Motomiya,Manabu Waseda,Masaaki Miyakawa,Yoshikazu Naka,Yasuo Terauchi,Yasushi Tanaka,Ikuro Matsuba +36 more
TL;DR: Glucose-dependent suppression of glucagon secretion by sitagliptin may be useful in patients with impaired insulin secretion as well as concomitantly with insulin irrespective of the insulin regimen, duration of insulin treatment, and concomitant medications.